Life Science Investing Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
Life Science Investing Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
Life Science Investing Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Life Science Investing Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635
Life Science Investing Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
life science investing Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
life science investing Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
life science investing Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635
life science investing Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
